Japan has approved use of a new basal insulin from Novo Nordisk, insulin degludec. It is being promoted by the company as having a duration of action up to 42 hours. The press release is here.
The first “smart” insulin pen has finally hit the market. This is a big moment for diabetes care, as the digital toolbox expands. (I wrote a post in 2013 about this topic, asking for someone to make a
The Swedish Obese Subjects study is a fabulous example of how very-useful practical knowledge can come out of a well-conducted cohort study. Not everything has to be a prospective randomized controll